Plus Therapeutics Highlights Three REYOBIQ(TM) Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Plus Therapeutics Highlights Three REYOBIQ(TM) Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting GlobeNewswire December 04, 2025 Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal, supporting continued Phase 2 […]